Q1 EPS Estimate for Revolution Medicines Lowered by Analyst

Revolution Medicines, Inc. (NASDAQ:RVMD) – Analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of Revolution Medicines in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.09) per share for the quarter, down from their prior forecast of ($0.92). HC Wainwright has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.17) EPS and FY2025 earnings at ($4.51) EPS.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11).

A number of other research analysts have also issued reports on the company. Needham & Company LLC reduced their price target on Revolution Medicines from $60.00 to $59.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Piper Sandler boosted their price target on Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Revolution Medicines from $63.00 to $71.00 and gave the company an “overweight” rating in a report on Tuesday, December 3rd. Wedbush restated an “outperform” rating and issued a $67.00 price objective on shares of Revolution Medicines in a report on Thursday, February 27th. Finally, Guggenheim upped their price objective on Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Twelve investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $66.31.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $39.22 on Thursday. Revolution Medicines has a 1 year low of $29.55 and a 1 year high of $62.40. The stock has a fifty day moving average of $41.69 and a two-hundred day moving average of $46.06. The firm has a market capitalization of $7.29 billion, a PE ratio of -10.92 and a beta of 1.46.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RVMD. KBC Group NV raised its position in Revolution Medicines by 12.9% during the third quarter. KBC Group NV now owns 3,221 shares of the company’s stock valued at $146,000 after buying an additional 368 shares during the period. CIBC Asset Management Inc acquired a new position in Revolution Medicines during the third quarter valued at $216,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Revolution Medicines during the third quarter valued at $1,220,000. Intech Investment Management LLC acquired a new position in Revolution Medicines during the third quarter valued at $1,709,000. Finally, Charles Schwab Investment Management Inc. raised its position in Revolution Medicines by 58.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,763,117 shares of the company’s stock valued at $79,957,000 after buying an additional 653,433 shares during the period. 94.34% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 11,714 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $531,815.60. Following the sale, the insider now directly owns 325,056 shares of the company’s stock, valued at $14,757,542.40. The trade was a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Margaret A. Horn sold 4,329 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $45.40, for a total value of $196,536.60. Following the sale, the chief operating officer now directly owns 127,991 shares in the company, valued at $5,810,791.40. This trade represents a 3.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,678 shares of company stock valued at $847,981 over the last three months. Company insiders own 8.00% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.